6 个月
Zacks.com on MSNAura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer StudyShares of Aura Biosciences AURA gained 7.9% on Sept. 12 after the company announced encouraging data from a phase II study ...
The most widely accepted theory is that nerve endings resting on the outer surface of the membranes that enclose the brain are responsible for the headaches that follow an aura. The new study ...
The four exoplanets orbit Barnard’s Star so closely that their years last only a few Earth days. They are probably rocky and, ...
Aura Intelligence is not just tracking workforce data, it is shaping the future of Organizational Decision Intelligence ...
BOSTON - Aura Biosciences, Inc ... The new data stems from a study evaluating the safety and efficacy of bel-sar, a Virus-like-Drug-Conjugate (VDC), in patients with NMIBC.
The researchers enrolled 72 patients who had migraine without aura. Following a 4-week run ... During the 3-month study period, those in the yoga group had significantly fewer headache days ...
In the coming months, the Company will conduct a review of the feasibility study and evaluate alternatives to optimize scale, risk, and return profile of the project. Concurrently, Aura will implement ...
In the coming months, the Company will conduct a review of the feasibility study and evaluate alternatives to optimize scale, risk, and return profile of the project. Concurrently, Aura will ...
Aura’s inaugural Safety Day, called by “D Day” was held on October 10 and showcased the Company’s unwavering commitment to safety. The event began with an impactful video message from Aura ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果